Limited evidence that vitamin D supplements of any benefit for patients with HIV
Raltegravir kinder to bones and body fat than boosted protease inhibitors in Spanish trial
Patients on HIV therapy have an increased risk of stress and fragility fractures; no link to specific drug
Raltegravir combined with Kaletra associated with good preservation of bone density over 96 weeks
Marker of cardiovascular disease also associated with bone problems in patients with HIV
Doubt remains if HIV therapy increases the risk of fragility fractures
